{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002765","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.165389+00:00","generated_at":"2026-06-02T03:18:46.664838+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cassava Sciences Q1 net income $25M; Phase 3 Alzheimer's trials on track with >1,900 patients","bullets":["Net income of $25.0M vs net loss $24.3M in Q1 2023; non-cash warrant gain drove the swing.","$126.3M in gross proceeds from warrant exercise; cash & equivalents $124.2M, no debt as of March 31.","Over 1,900 patients randomized across two Phase 3 simufilam trials; >735 patients have completed.","Top-line data for 52-week RETHINK-ALZ expected year-end 2024; 76-week REFOCUS-ALZ data mid-2025.","Q1 R&D spend $16.2M, down from $22.1M YoY; H1 2024 operating cash burn guided at $35-45M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002765","json":"https://secwatch.observer/filing/0001171843-24-002765.json","markdown":"https://secwatch.observer/filing/0001171843-24-002765.md","text":"https://secwatch.observer/filing/0001171843-24-002765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324002765/0001171843-24-002765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324002765/f8k_051024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:18:46.664838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}